Drug
GO-203-2C
GO-203-2C is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Completed1
Withdrawn1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
completed133%
withdrawn133%
active_not_recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruitingphase_1
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02204085
withdrawnphase_1
GO-203-2C + Bortezomib For Relapsed Or Refractory MM
NCT02658396
completedphase_1
Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas
NCT01279603
Clinical Trials (3)
Showing 3 of 3 trials
NCT02204085Phase 1
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02658396Phase 1
GO-203-2C + Bortezomib For Relapsed Or Refractory MM
NCT01279603Phase 1
Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3